ENTBF
Price
$0.09
Change
+$0.02 (+28.57%)
Updated
Jul 24 closing price
Capitalization
1.02M
GERN
Price
$1.26
Change
-$0.02 (-1.56%)
Updated
Jul 25 closing price
Capitalization
802.52M
11 days until earnings call
Interact to see
Advertisement

ENTBF vs GERN

Header iconENTBF vs GERN Comparison
Open Charts ENTBF vs GERNBanner chart's image
ENTHEON BIOMEDICAL
Price$0.09
Change+$0.02 (+28.57%)
Volume$531
Capitalization1.02M
Geron
Price$1.26
Change-$0.02 (-1.56%)
Volume$6.76M
Capitalization802.52M
ENTBF vs GERN Comparison Chart in %
Loading...
ENTBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTBF vs. GERN commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTBF is a Hold and GERN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ENTBF: $0.09 vs. GERN: $1.26)
Brand notoriety: ENTBF and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTBF: 60% vs. GERN: 68%
Market capitalization -- ENTBF: $1.02M vs. GERN: $802.52M
ENTBF [@Biotechnology] is valued at $1.02M. GERN’s [@Biotechnology] market capitalization is $802.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTBF’s FA Score shows that 0 FA rating(s) are green whileGERN’s FA Score has 0 green FA rating(s).

  • ENTBF’s FA Score: 0 green, 5 red.
  • GERN’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTBF is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTBF’s TA Score shows that 4 TA indicator(s) are bullish while GERN’s TA Score has 3 bullish TA indicator(s).

  • ENTBF’s TA Score: 4 bullish, 4 bearish.
  • GERN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ENTBF is a better buy in the short-term than GERN.

Price Growth

ENTBF (@Biotechnology) experienced а +2.96% price change this week, while GERN (@Biotechnology) price change was +1.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

GERN is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($803M) has a higher market cap than ENTBF($1.02M). ENTBF YTD gains are higher at: -36.663 vs. GERN (-64.407). ENTBF has higher annual earnings (EBITDA): -403.94K vs. GERN (-114.49M). GERN has more cash in the bank: 397M vs. ENTBF (525K). GERN has higher revenues than ENTBF: GERN (116M) vs ENTBF (0).
ENTBFGERNENTBF / GERN
Capitalization1.02M803M0%
EBITDA-403.94K-114.49M0%
Gain YTD-36.663-64.40757%
P/E RatioN/AN/A-
Revenue0116M-
Total Cash525K397M0%
Total DebtN/A122M-
FUNDAMENTALS RATINGS
GERN: Fundamental Ratings
GERN
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
92
P/E GROWTH RATING
1..100
76
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENTBFGERN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
74%
Momentum
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 7 days ago
87%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 7 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
73%
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 3 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ENTBF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCDAX194.201.76
+0.91%
Vanguard Consumer Discretionary Idx Adm
HSMVX13.180.04
+0.30%
Hartford Small Cap Value R6
MFCIX42.500.11
+0.26%
Meridian Contrarian Investor
MDCPX26.790.01
+0.04%
BlackRock Balanced Investor A
FERRX11.93-0.01
-0.08%
First Eagle Global Real Assets R6

ENTBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTBF has been loosely correlated with SER. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTBF jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTBF
1D Price
Change %
ENTBF100%
N/A
SER - ENTBF
35%
Loosely correlated
-2.35%
IMRX - ENTBF
31%
Poorly correlated
+1.50%
XTLB - ENTBF
29%
Poorly correlated
-2.51%
GERN - ENTBF
27%
Poorly correlated
-1.56%
LABFF - ENTBF
20%
Poorly correlated
N/A
More

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-1.56%
SER - GERN
65%
Loosely correlated
-2.35%
DAWN - GERN
41%
Loosely correlated
+0.28%
SYRE - GERN
39%
Loosely correlated
+1.08%
DNTH - GERN
37%
Loosely correlated
-1.33%
UTHR - GERN
37%
Loosely correlated
-0.62%
More